This project was submitted in the following language: English (en).
COVID-19

Descripción del proyecto

Rapid development of novel antiviral treatments to reduce the impact of the current coronavirus pandemic

In this project we develop a new class of antimicrobial peptides (AMPs) entitled Synthetic Antimicrobial Antibiofilm Peptides (SAAPs), which are best in class compounds and have shown to be highly effective against bacterial infections in cell culture and animal models. In addition we investigate the potential of the SAAP family (a set of 1026 peptides) as treatment for SARS-CoV-2 infections

Remko van Leeuwen

CEO

Remko van Leeuwen (CEO) is a medical doctor by training and has more than 30 years of academic and industrial research experience in infectious diseases and as a team leader he has successfully conducted numerous clinical and pre-clinical drug development programs

Más información

País, región

Países Bajos [Zuid-Holland]

Fecha de comienzo

julio 2020

Coste estimado del proyecto

2.5 millones de euros

sector

Investigación, desarrollo e innovación

Industry for SMEs & Mid-Caps

Titularidad de los activos

Privada

Tipo de proyecto

Otros

Estado del proyecto

Planificación

Tipo de ingresos

Basados en el mercado

Creación de empleo prevista

5

Justificación económica / modelo empresarial

Respiratory virus infections like SARS—CoV-2 can cause acute respiratory distress syndrome and secondary bacterial infections. In severe cases, it can lead to life-threatening pathological changes such as multiple organ failure, sepsis, and diffuse intravascular coagulation. These complications have been one of the major reasons for the death of patients infected with novel coronavirus. Proper treatment of such complications as acute lung injuries thus makes a major difference to the survivability of the disease. Some analysts, such as Geoff Meacham of Bank of America Merrill Lynch, predict that total CoViD-19-related sales for an antiwould reach a one-time figure of $2.5 billion. This sales forecast could be significantly higher when SAAPs prove effective against more corona virus variants (e.g. could be protective in future outbreaks).
Obviously, pulmonary infections are a key component of CoViD-19 morbidity but can also be seen as a stand-alone market opportunity. WHO figures show that lower respiratory infections are the most deadly communicable disease, causing 3.0 million deaths worldwide in 2016. Madam Therapeutics aims to license the peptide to a larger pharma player after establishing proof of concept.

Detalles de la financiación

Financiación del proyecto garantizada: 0.25 millones de euros (10 %)

Contribución propia: 0.25 millones de euros (10 %)

Fuente de financiación: Privada

Madam Therapeutics has raised 1,1M in private equity in Sept 2018, via Angel investors

El promotor ha recibido/solicitado apoyo financiero de la UE/el BEI en relación con este proyecto.

Obstáculos existentes o potenciales para la realización del proyecto / Riesgos potenciales

This is a drug development program. These by nature always carry a high risk. Nonetheless we need to remain all focused on finding a treatment against the coronavirus, while there’s another, major threat still lurking: superbugs. The pandemic is a stark reminder of the need to be prepared for public health crises, particularly the growing danger of antibiotic-resistant bacteria, which clearly outweighs the risks involved.

Información adicional sobre el proyecto

BioWorld Today, a leading news source for the biotech industry from Thomson Reuters, has recently described AMPs such as our SAAPs as the most exciting developments in the anti-microbial development . In a commentary in Science Translational Medicine , several unique characterises of our SAAP family are highlighted. The commentary mentioned that our SAAPs represent “the first published demonstration of the killing of persisters bacteria”.

Publicación: 10/06/2020 | Última actualización: 10/06/2020

La Comisión no ofrece ninguna garantía y no está facultada para manifestar, ni expresa ni implícitamente, que la información del proyecto está libre de error. La información del proyecto se ofrece sin ningún tipo de garantías o condiciones en cuanto a su exactitud.